Ibrance is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Palbociclib.
| Product ID | 0069-0188_54fa32a8-a9aa-4643-a227-ddf95ec4dd05 |
| NDC | 0069-0188 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Ibrance |
| Generic Name | Palbociclib |
| Dosage Form | Capsule |
| Route of Administration | ORAL |
| Marketing Start Date | 2015-02-03 |
| Marketing Category | NDA / NDA |
| Application Number | NDA207103 |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Substance Name | PALBOCICLIB |
| Active Ingredient Strength | 100 mg/1 |
| Pharm Classes | Kinase Inhibitor [EPC],Kinase Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2015-02-03 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA207103 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2015-02-03 |
| Ingredient | Strength |
|---|---|
| PALBOCICLIB | 100 mg/1 |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0069-0187 | Ibrance | palbociclib |
| 0069-0188 | Ibrance | palbociclib |
| 0069-0189 | Ibrance | palbociclib |
| 0069-0284 | Ibrance | palbociclib |
| 0069-0486 | Ibrance | palbociclib |
| 0069-0688 | Ibrance | palbociclib |
| 63539-187 | Ibrance | palbociclib |
| 63539-188 | Ibrance | palbociclib |
| 63539-189 | Ibrance | palbociclib |
| 63539-284 | Ibrance | palbociclib |
| 63539-486 | Ibrance | palbociclib |
| 63539-688 | Ibrance | palbociclib |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() IBRANCE 86314613 4928206 Live/Registered |
Pfizer Inc. 2014-06-19 |
![]() IBRANCE 85444239 4518147 Live/Registered |
Pfizer Inc. 2011-10-11 |
![]() IBRANCE 77448185 not registered Dead/Abandoned |
Pfizer Inc. 2008-04-15 |